Replies to post #279285 on Avid Bioservices Inc (CDMO)

[goodJohnhunting]

I think the 'IL' levels will do better because we know that there is a direct relation between IL-10/IL-12 changes when Bavituximab is in the mix. Patients with High IL-10 and/or Low IL-12 may benefit more from Bavi as bavi decreases IL-10 (the immuno suppression unblocking part) and increases IL-12 (the so needed immuno-activation part) which will result in immune system activation which in turn will lead to cell damage repair/evac, tumour fighting and adaptive immune system activity against relapse.

How can anything be confirmed as, "we know that there is a direct relation between IL-10/IL-12 changes when Bavituximab is in the mix", when the data mining proved that binding is unstable, unpredictable, and subject to unsubscribed variances?

Until these "unsubscribed variances" are known, and PK/PD is established, then all is noise, and the 2tonelephant lives on, IMO.

All the best,
John

[eb0783]

I would not be calling it a joke as jake did but I think identifying any biomarker and using it to file a provisional patent, which would easily allow any number of other biomarkers to be added as they are identified by further analysis, was a good strategic move.

You said

jakeDM, you seem to be better informed then average. You are correct, b2gp1 is one of many that they chose to test. The patent will create a "priority date" for their case.
……………………………………….
A good Joke, you have to give them that :)

After that they can tie the observation to one or more of the many other biomarkers that relates to their case and use the priority date (since the US is now in the first-to-file system).

That goes right along with my discussion of it with Shelley Fussey at the ASM

On a sidebar with just Shelley and I, Shelly Fussey said they have filed a detailed provisional patent on the Biomarkers which sets the filed date, keep it from being published/shared, and allows inexpensive additions/updates for a number of months (forget if it was 6, 9, or 12). Basically, we the public, and their competitors, will not be able to access it for 18mos. It also adds another year to the patent protection that way.